ES2527859T3 - Mejoras referentes a vesículas de membrana externa meningocócicas - Google Patents

Mejoras referentes a vesículas de membrana externa meningocócicas Download PDF

Info

Publication number
ES2527859T3
ES2527859T3 ES05782411.2T ES05782411T ES2527859T3 ES 2527859 T3 ES2527859 T3 ES 2527859T3 ES 05782411 T ES05782411 T ES 05782411T ES 2527859 T3 ES2527859 T3 ES 2527859T3
Authority
ES
Spain
Prior art keywords
vme
ref
meningococcal
vaccine
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05782411.2T
Other languages
English (en)
Spanish (es)
Inventor
Philipp Oster
Rino Rappuoli
Mariagrazia Pizza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics SRL
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics SRL, Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics SRL
Application granted granted Critical
Publication of ES2527859T3 publication Critical patent/ES2527859T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ES05782411.2T 2004-09-03 2005-09-05 Mejoras referentes a vesículas de membrana externa meningocócicas Expired - Lifetime ES2527859T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0419627 2004-09-03
GBGB0419627.5A GB0419627D0 (en) 2004-09-03 2004-09-03 Immunogenic bacterial vesicles with outer membrane proteins
PCT/IB2005/002801 WO2006024946A2 (en) 2004-09-03 2005-09-05 Improvements relating to meningococcal outer membrane vesicles

Publications (1)

Publication Number Publication Date
ES2527859T3 true ES2527859T3 (es) 2015-01-30

Family

ID=33156002

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05782411.2T Expired - Lifetime ES2527859T3 (es) 2004-09-03 2005-09-05 Mejoras referentes a vesículas de membrana externa meningocócicas

Country Status (13)

Country Link
US (1) US8808711B2 (https=)
EP (1) EP1784213B1 (https=)
JP (2) JP2008511608A (https=)
CN (2) CN101862451A (https=)
AU (1) AU2005278896B2 (https=)
BR (1) BRPI0514883A (https=)
CA (1) CA2578588A1 (https=)
ES (1) ES2527859T3 (https=)
GB (1) GB0419627D0 (https=)
MX (1) MX2007002633A (https=)
NZ (1) NZ553521A (https=)
RU (1) RU2420312C2 (https=)
WO (1) WO2006024946A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2004225T3 (pl) * 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
UA99659C2 (uk) * 2008-05-30 2012-09-10 Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
GB0822634D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
AU2011288203A1 (en) 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
EP3299467B1 (en) 2012-02-02 2021-08-11 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
EP3693010A1 (en) 2012-04-06 2020-08-12 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
AU2013276083B2 (en) 2012-06-14 2018-04-05 Institut Pasteur Vaccines for serogroup X meningococcus
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
JP6283674B2 (ja) 2012-09-18 2018-02-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 外膜小胞
JP2016507543A (ja) 2013-02-07 2016-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 小胞を含む医薬組成物
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
EP3169357B1 (en) 2014-07-17 2018-11-07 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
JP6687597B2 (ja) * 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
US12109259B2 (en) * 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
EP3678693A1 (en) 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Bacterial extracellular vesicles
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
ATE173634T1 (de) 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
CA2297072A1 (en) 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
WO1999061053A1 (en) 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US20060057160A1 (en) * 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) * 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
US7031284B2 (en) * 2003-03-03 2006-04-18 Interdigital Technology Corporation Wireless communication method and apparatus for optimizing multi-user detection
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CA2654706A1 (en) * 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine

Also Published As

Publication number Publication date
US8808711B2 (en) 2014-08-19
JP2008511608A (ja) 2008-04-17
CN101115501A (zh) 2008-01-30
CN101862451A (zh) 2010-10-20
EP1784213B1 (en) 2014-10-29
US20080063665A1 (en) 2008-03-13
AU2005278896A1 (en) 2006-03-09
RU2007111838A (ru) 2008-10-10
MX2007002633A (es) 2007-05-15
WO2006024946A3 (en) 2006-11-30
EP1784213A2 (en) 2007-05-16
RU2420312C2 (ru) 2011-06-10
BRPI0514883A (pt) 2008-06-24
WO2006024946A2 (en) 2006-03-09
CA2578588A1 (en) 2006-03-09
GB0419627D0 (en) 2004-10-06
AU2005278896B2 (en) 2011-12-22
NZ553521A (en) 2010-01-29
JP2011236254A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
ES2527859T3 (es) Mejoras referentes a vesículas de membrana externa meningocócicas
ES2507499T3 (es) Vesículas bacterianas inmunogénicas con proteínas de membrana externa
RU2475496C2 (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
ES2401481T3 (es) Inmunización contra el serogrupo y del meningococo usando proteínas
ES2562259T3 (es) Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
US8790654B2 (en) Glycosylceramide adjuvant for saccharide antigens
ES2848048T3 (es) Composiciones inmunogénicas
CN102724988B (zh) 脑膜炎球菌fHBP多肽的表达
US20130071422A1 (en) Adjuvanted vaccines for serogroup b meningococcus
ES2398664T3 (es) Procedimientos de cultivo semicontinuo de estreptococos
JP2012502013A (ja) 外膜小胞初回刺激−タンパク質追加免疫ワクチン
US20120121714A1 (en) Compositions with antigens adsorbed to calcium phosphate
ES2727798T3 (es) Polipéptidos de FHPP meningocócicos